All In Biotech

Drug Trial Radar · NCT06055985

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Nov 17, 2023

Primary completion

Mar 31, 2025

Study completion Apr 11, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).

Conditions

  • Parkinson Disease

Interventions

  • PlaceboOther

    Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.

  • UCB0022Drug

    Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Visit 9 (Day 70) in the average number of hours/day of OFF time, as assessed by the study participant-completed Hauser PD symptoms diary over 3 consecutive daysTime frame: From Baseline (Day 1) to Visit 9 (Day 70)

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Pd0060 50506

    Phoenix, Arizona

  • Pd0060 50590

    Scottsdale, Arizona

  • Pd0060 50608

    Little Rock, Arkansas

  • Pd0060 50519

    Fountain Valley, California

  • Pd0060 50428

    Fresno, California

  • Pd0060 50601

    Loma Linda, California

  • Pd0060 50589

    Los Alamitos, California

  • Pd0060 50587

    Los Angeles, California

  • Pd0060 50452

    Pasadena, California

  • Pd0060 50598

    Englewood, Colorado

  • Pd0060 50628

    New Haven, Connecticut

  • Pd0060 50610

    Newark, Delaware

  • Pd0060 50600

    Altamonte Springs, Florida

  • Pd0060 50616

    Aventura, Florida

  • Pd0060 50596

    Boca Raton, Florida

  • Pd0060 50524

    Bradenton, Florida

  • Pd0060 50647

    DeLand, Florida

  • Pd0060 50577

    Doral, Florida

  • Pd0060 50584

    Hollywood, Florida

  • Pd0060 50582

    Miami, Florida

  • Pd0060 50579

    Miami, Florida

  • Pd0060 50449

    Miami, Florida

  • Pd0060 50580

    Miami, Florida

  • Pd0060 50597

    Naples, Florida

  • Pd0060 50591

    Ocala, Florida

  • Pd0060 50605

    Port Orange, Florida

  • Pd0060 50620

    St. Petersburg, Florida

  • Pd0060 50603

    Tampa, Florida

  • Pd0060 50585

    Winter Park, Florida

  • Pd0060 50075

    Augusta, Georgia

  • Pd0060 50595

    Indianapolis, Indiana

  • Pd0060 50319

    Iowa City, Iowa

  • Pd0060 50074

    Kansas City, Kansas

  • Pd0060 50561

    Lexington, Kentucky

  • Pd0060 50615

    Boston, Massachusetts

  • Pd0060 50085

    Boston, Massachusetts

  • Pd0060 50627

    North Dartmouth, Massachusetts

  • Pd0060 50110

    Ann Arbor, Michigan

  • Pd0060 50545

    East Lansing, Michigan

  • Pd0060 50386

    Farmington Hills, Michigan

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.